Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC plus immune checkpoint inhibitors for locally advanced biliary tract cancer
ChiCTR2400091465Phase 2Recruiting
- Sponsor
- Liaoning Province Cancer Hospital
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab + lenvatinib + gemcitabine + cisplatin in biliary cancer, sponsored by Liaoning Province Cancer Hospital. Primary endpoint: Objective response rate. Started Oct 2024; status: recruiting.
02
Drugs
durvalumab + lenvatinib + gemcitabine + cisplatin
03
Conditions
biliary cancer
Beyond the preview
Go deeper on ChiCTR2400091465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091465.